Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F18%3AN0000010" target="_blank" >RIV/00064190:_____/18:N0000010 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/18:E0107230
Result on the web
<a href="https://onlinelibrary-1wiley-1com-1wos.han.medvik.cz/resolve/doi?DOI=10.1002/nau.23566" target="_blank" >https://onlinelibrary-1wiley-1com-1wos.han.medvik.cz/resolve/doi?DOI=10.1002/nau.23566</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/nau.23566" target="_blank" >10.1002/nau.23566</a>
Alternative languages
Result language
angličtina
Original language name
Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study
Original language description
Aims: To assess the efficacy and safety of mirabegron in the treatment of neurogenic detrusor overactivity. Methods: This prospective, multicenter, randomized, double-blind, placebo-controlled study was conducted in three tertiary centers, and included 78 patients suffering from spinal cord injury or multiple sclerosis. Patients were randomized for Mirabegron 50 mg (Group A) or placebo (Group B). Urodynamic parameters, the 24h pad-weight test, and patient-reported outcomes were assessed. Safety assessments included monitoring the incidence and severity of adverse events. Changes in time and differences between groups were assessed with nonparametric Kruskal-Wallis one-way analysis of variance; P <= 0.05 was considered statistically significant. Results: In total, 66 patients were eligible for inclusion in the final analysis. There was a significant increase of volume at the first detrusor contraction (P=0.00047) and an improvement in bladder compliance (P=0.0041) in the mirabegron group compared with the placebo-treated group, whereas the increase in cystometric capacity did not reach statistical significance (P=0.061). There was a clear tendency to reduced urine leakage (P=0.056) in Group A. There were significant changes in all the patient-reported outcomes, favoring the mirabegron group. The incidence of drug-related adverse events was 3.13%. Conclusions: Mirabegron (50 mg) improved both urodynamic variables and patient-reported outcomes in patients with NDO. The treatment was tolerated well.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
NEUROUROLOGY AND URODYNAMICS
ISSN
0733-2467
e-ISSN
1520-6777
Volume of the periodical
37
Issue of the periodical within the volume
7
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
2226-2233
UT code for WoS article
000444957900022
EID of the result in the Scopus database
2-s2.0-85052201981